CA2900008C - Protein antigens that provide protection against pneumococcal colonization and/or disease - Google Patents

Protein antigens that provide protection against pneumococcal colonization and/or disease

Info

Publication number
CA2900008C
CA2900008C CA2900008A CA2900008A CA2900008C CA 2900008 C CA2900008 C CA 2900008C CA 2900008 A CA2900008 A CA 2900008A CA 2900008 A CA2900008 A CA 2900008A CA 2900008 C CA2900008 C CA 2900008C
Authority
CA
Canada
Prior art keywords
antigens
pneumococcal
present
compositions
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2900008A
Other languages
English (en)
French (fr)
Other versions
CA2900008A1 (en
Inventor
Richard Malley
Yingjie Lu
Fan Zhang
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CA2900008A1 publication Critical patent/CA2900008A1/en
Application granted granted Critical
Publication of CA2900008C publication Critical patent/CA2900008C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2900008A 2013-02-07 2014-02-07 Protein antigens that provide protection against pneumococcal colonization and/or disease Active CA2900008C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762062P 2013-02-07 2013-02-07
US61/762,062 2013-02-07
PCT/US2014/015254 WO2014124228A1 (en) 2013-02-07 2014-02-07 Protein antigens that provide protection against pneumococcal colonization and/or disease

Publications (2)

Publication Number Publication Date
CA2900008A1 CA2900008A1 (en) 2014-08-14
CA2900008C true CA2900008C (en) 2025-10-07

Family

ID=51300148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900008A Active CA2900008C (en) 2013-02-07 2014-02-07 Protein antigens that provide protection against pneumococcal colonization and/or disease

Country Status (7)

Country Link
US (3) US11576958B2 (enExample)
EP (2) EP2953638B1 (enExample)
JP (2) JP6494527B2 (enExample)
AU (2) AU2014214844B2 (enExample)
CA (1) CA2900008C (enExample)
ES (1) ES2959258T3 (enExample)
WO (1) WO2014124228A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835630A1 (en) 2011-05-11 2012-11-15 Richard Malley Modified biotin-binding protein, fusion proteins thereof and applications
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
EP3436061A4 (en) * 2016-03-31 2019-12-04 Liffey Biotech Limited Saccharide-polypeptide-conjugate compositions and methods of use thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN110392690B (zh) * 2017-02-24 2024-01-30 默沙东有限责任公司 肺炎球菌缀合物疫苗制剂
CN110730670A (zh) 2017-03-28 2020-01-24 儿童医疗中心有限公司 基于多抗原提呈系统(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途
WO2018183666A1 (en) 2017-03-31 2018-10-04 Boston Medical Center Corporation Methods and compositions using highly converved pneumococcal surface proteins
US12090198B2 (en) * 2017-05-22 2024-09-17 The Children's Medical Center Corporation Combined vaccine against mycobacterium tuberculosis
TWI850197B (zh) 2017-06-23 2024-08-01 美國馬里蘭大學巴爾的摩分校 免疫原性組成物
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
GB201807303D0 (en) * 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
GB201807380D0 (en) 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
CA3111273C (en) * 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
KR20210088535A (ko) * 2018-09-12 2021-07-14 더 칠드런스 메디칼 센터 코포레이션 폐렴구균 융합 단백질 백신
SG11202102007UA (en) * 2018-09-12 2021-03-30 Affinivax Inc Multivalent pneumococcal vaccines
EP4114844A4 (en) * 2020-03-03 2024-04-10 Mayo Foundation for Medical Education and Research Zika virus polypeptides
WO2022031087A1 (ko) * 2020-08-07 2022-02-10 (주)셀트리온 폐렴구균 다당류-세포벽 유래 물질 접합체를 포함하는 면역원성 조성물
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2024192346A1 (en) * 2023-03-16 2024-09-19 Affinivax, Inc. Immunogenic compositions
WO2024229176A1 (en) 2023-05-04 2024-11-07 Affinivax, Inc. Rhizavidin variants
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB1502774A (en) 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4242501A (en) 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
ATE77488T1 (de) 1986-03-06 1992-07-15 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8906795D0 (en) 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0372423A (ja) 1989-05-26 1991-03-27 Green Cross Corp:The パーフルオロカーボン化合物含有乳化製剤
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5674698A (en) 1992-09-14 1997-10-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
JPH11502820A (ja) 1995-03-22 1999-03-09 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 有機シアン化試薬により活性化された可溶性炭水化物を使用する免疫原性構築物の製造
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
NZ331164A (en) 1996-02-09 2000-02-28 Univ Liege Vaccines against varicella zoster virus gene 63 product
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
AU5194598A (en) 1996-10-31 1998-05-22 Human Genome Sciences, Inc. (streptococcus pneumoniae) antigens and vaccines
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
JP2002504096A (ja) 1997-04-24 2002-02-05 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン タンパク質−多糖ワクチンの調製のための未修飾タンパク質とハロアシルまたはジハロアシル誘導体化された多糖との結合
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
KR100619350B1 (ko) 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
WO1999012416A1 (en) 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
EP1144640A3 (en) * 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
JP2002531055A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2322306T3 (es) 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
GB9928678D0 (en) 1999-12-03 2000-02-02 Provalis Uk Ltd Streptococcus pneumoniae antigens
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
SE0003538D0 (sv) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
AU2002364783A1 (en) 2001-11-21 2003-06-10 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism
RU2378008C2 (ru) 2002-05-14 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20060121058A1 (en) 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
EP1558280B1 (en) 2002-11-07 2014-01-08 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP2311991A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
BRPI0410423A (pt) 2003-05-07 2006-06-06 Sanofi Pasteur Inc processo de imunogenicidade melhorada para vacinação meningocócica
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
JP5097400B2 (ja) 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
US7786288B2 (en) 2003-10-23 2010-08-31 Karp Nelson M Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20050226899A1 (en) 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
JP2008508855A (ja) 2004-04-27 2008-03-27 インターツェル・アクチェンゲゼルシャフト Ｔｄ抗原
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
CA2576083A1 (en) 2004-08-18 2006-02-23 Joel Weiner Protein production method utilizing yebf
FI20041396A0 (fi) 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
BRPI0606481A2 (pt) 2005-01-20 2009-06-30 Isconova Ab composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina
CA2597489A1 (en) 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
US20090148894A1 (en) 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
BRPI0615420A2 (pt) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinação múltipla que inclui meningococo do sorogrupo c
AU2006321888A1 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
WO2007081583A2 (en) 2006-01-04 2007-07-19 Children's Medical Center Corporation Anti-pneumococcal preparations and methods of use
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
EP1988918A4 (en) 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
WO2007150020A1 (en) 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
ES2517869T3 (es) 2006-09-12 2014-11-04 Alphavax, Inc. Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
ES2673823T3 (es) 2006-11-03 2018-06-25 Alphavax, Inc. Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
EP2104512A2 (en) 2006-12-21 2009-09-30 Emergent Product Development UK Limited Streptococcus proteins, and their use in vaccination
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
PL2468869T3 (pl) 2007-01-31 2015-08-31 Pfenex Inc Bakteryjna sekwencja wiodąca dla zwiększonej ekspresji
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
AU2008287286B2 (en) 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
CN104873965B (zh) 2007-06-26 2018-09-11 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20100168392A1 (en) 2007-08-10 2010-07-01 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
KR101661946B1 (ko) 2007-08-31 2016-10-05 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US20090068288A1 (en) 2007-09-07 2009-03-12 Wayne Kruger Topical antiseptic veterinary solution
US9125863B2 (en) 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
WO2010078027A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
WO2010071986A1 (en) 2008-12-24 2010-07-01 Sanofi Pasteur Limited Modified steptococcus pneumonia pneumolysin (ply) polypeptides
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
WO2010135749A1 (en) 2009-05-22 2010-11-25 Genocea Biosciences Inc. Herpes simplex virus type2: compositions and methods for eliciting an immune response
IN2012DN00791A (enExample) 2009-06-29 2015-06-26 Genocea Biosciences Inc
IN2012DN03418A (enExample) 2009-10-09 2015-10-23 Childrens Medical Center
EP2335721A1 (en) 2009-12-21 2011-06-22 Institut Pasteur Streptavidin and Biotin-based antigen delivery system
US20110159040A1 (en) 2009-12-30 2011-06-30 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
WO2011137354A2 (en) 2010-04-30 2011-11-03 Augmenta Biologicals, Llc Delivery proteins
US20120135025A1 (en) 2010-10-20 2012-05-31 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
JP6126993B2 (ja) 2011-01-20 2017-05-10 ジェノセア バイオサイエンシーズ， インコーポレイテッド 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物
CA2835630A1 (en) 2011-05-11 2012-11-15 Richard Malley Modified biotin-binding protein, fusion proteins thereof and applications
WO2013109995A2 (en) 2012-01-20 2013-07-25 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CN108367063A (zh) 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
SG11202102007UA (en) 2018-09-12 2021-03-30 Affinivax Inc Multivalent pneumococcal vaccines
KR20210088535A (ko) 2018-09-12 2021-07-14 더 칠드런스 메디칼 센터 코포레이션 폐렴구균 융합 단백질 백신

Also Published As

Publication number Publication date
EP4272750A2 (en) 2023-11-08
AU2014214844A1 (en) 2015-08-13
EP2953638B1 (en) 2023-07-05
EP4272750A3 (en) 2024-01-24
AU2014214844B2 (en) 2017-12-14
AU2018201768A1 (en) 2018-04-05
ES2959258T3 (es) 2024-02-22
JP6916828B2 (ja) 2021-08-11
JP2016509011A (ja) 2016-03-24
US12083173B2 (en) 2024-09-10
WO2014124228A1 (en) 2014-08-14
US20150374811A1 (en) 2015-12-31
JP2019108375A (ja) 2019-07-04
JP6494527B2 (ja) 2019-04-03
US20250114443A1 (en) 2025-04-10
US11576958B2 (en) 2023-02-14
CA2900008A1 (en) 2014-08-14
AU2018201768B2 (en) 2020-03-12
EP2953638A4 (en) 2016-08-03
EP2953638A1 (en) 2015-12-16
US20230081705A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
CA2900008C (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
MX2024006606A (es) Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BR112022019781A2 (pt) Vacina para o coronavírus
AU2008336295B2 (en) Improved immunizing composition
JOP20210148A1 (ar) تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
MX2018005256A (es) Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion.
MX392525B (es) Composiciones inmunogenicas para su uso en vacunas neumococicas
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
JP2015500827A5 (enExample)
AU2011258898A1 (en) Vaccine against Streptococcal infections based on recombinant proteins
MX2018003352A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
JP2015529677A5 (enExample)
Zhang et al. Protective immunity induced by the vaccination of recombinant Proteus mirabilis OmpA expressed in Pichia pastoris
WO2014165164A3 (en) Compositions and methods for treating autoimmune diseases
WO2011084967A3 (en) Methods and compositions for providing protective immunity in the elderly
MX2022009549A (es) Tratamiento que implica vacunacion con antigeno y agentes de union que se unen a pd-l1 y cd137.
MA38298A1 (fr) Vaccins monovalents et polyvalents contre leishmania

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204

EEER Examination request

Effective date: 20190204